127 related articles for article (PubMed ID: 30930427)
1. Ultrastructural Evidence of Glycosphingolipid Degradation After Enzyme Replacement Therapy in Patients With Fabry Disease.
Onoue K; Takemura G; Nakano T; Miyazaki N; Tsujimoto A; Watanabe T; Okada H; Kanamori H; Sugiura J; Kanaoka K; Ishihara S; Horii M; Akai Y; Sakaguchi Y; Saito Y
Circ J; 2019 Sep; 83(10):2081. PubMed ID: 30930427
[No Abstract] [Full Text] [Related]
2. Fabry disease - Vascular manifestations.
Karetova D; Bultas J; Dostalova G; Palecek T; Kovarnik T; Golan L; Linhart A
Vasa; 2010 May; 39(2):123-31. PubMed ID: 20464667
[TBL] [Abstract][Full Text] [Related]
3. Enzyme replacement therapy for Anderson-Fabry disease.
El Dib R; Gomaa H; Carvalho RP; Camargo SE; Bazan R; Barretti P; Barreto FC
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD006663. PubMed ID: 27454104
[TBL] [Abstract][Full Text] [Related]
4. The kidney in Fabry's disease.
Pisani A; Visciano B; Imbriaco M; Di Nuzzi A; Mancini A; Marchetiello C; Riccio E
Clin Genet; 2014 Oct; 86(4):301-9. PubMed ID: 24645664
[TBL] [Abstract][Full Text] [Related]
5. Fabry disease: enzyme replacement therapy.
Bongiorno MR; Pistone G; Aricò M
J Eur Acad Dermatol Venereol; 2003 Nov; 17(6):676-9. PubMed ID: 14761135
[TBL] [Abstract][Full Text] [Related]
6. Of the importance of the clinical phenotypes in the interpretation of the studies dealing with Fabry disease.
Mauhin W; Lidove O; Benveniste O
Orphanet J Rare Dis; 2019 Jan; 14(1):4. PubMed ID: 30616652
[TBL] [Abstract][Full Text] [Related]
7. Myofilament degradation and dysfunction of human cardiomyocytes in Fabry disease.
Chimenti C; Hamdani N; Boontje NM; DeCobelli F; Esposito A; Bronzwaer JG; Stienen GJ; Russo MA; Paulus WJ; Frustaci A; van der Velden J
Am J Pathol; 2008 Jun; 172(6):1482-90. PubMed ID: 18467700
[TBL] [Abstract][Full Text] [Related]
8. [Current status and future prospect of enzyme replacement therapy for Fabry disease].
Ohashi T
Rinsho Shinkeigaku; 2019 Jun; 59(6):335-338. PubMed ID: 31142708
[TBL] [Abstract][Full Text] [Related]
9. Enzyme therapy XVII: metabolic and immunologic evaluation of alpha- galactosidase A replacement in Fabry disease.
Desnick RJ; Dean KJ; Grabowski GA; Bishop DF; Sweeley CC
Birth Defects Orig Artic Ser; 1980; 16(1):393-413. PubMed ID: 6256019
[TBL] [Abstract][Full Text] [Related]
10. Analysis of placental tissue in Fabry disease with and without enzyme replacement therapy.
Bouwman MG; Hollak CE; van den Bergh Weerman MA; Wijburg FA; Linthorst GE
Placenta; 2010 Apr; 31(4):344-6. PubMed ID: 20189642
[TBL] [Abstract][Full Text] [Related]
11. Enzyme replacement therapy for Fabry disease: morphologic and histochemical changes in the urinary sediments.
Utsumi K; Mitsuhashi F; Asahi K; Sakurazawa M; Arii K; Komaba Y; Katsumata T; Katsura K; Kase R; Katayama Y
Clin Chim Acta; 2005 Oct; 360(1-2):103-7. PubMed ID: 16112661
[TBL] [Abstract][Full Text] [Related]
12. Authors’ reply.
Goláň L; Chang P
Drug Des Devel Ther; 2015; 9():5875. PubMed ID: 26918251
[No Abstract] [Full Text] [Related]
13. Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy was underpowered.
Ortiz A; Sanchez-Niño MD
Drug Des Devel Ther; 2015; 9():5873-4. PubMed ID: 26586938
[No Abstract] [Full Text] [Related]
14. Successful long-term enzyme replacement therapy in a young adult with Fabry disease.
Kampmann C; Kalkum G; Beck M; Whybra C
Clin Genet; 2013 Apr; 83(4):395-6. PubMed ID: 22881192
[No Abstract] [Full Text] [Related]
15. Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage.
Wang RY; Abe JT; Cohen AH; Wilcox WR
J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S369-74. PubMed ID: 18937048
[TBL] [Abstract][Full Text] [Related]
16. Gastroenterological complications of Anderson-Fabry disease.
Buda P; Książyk J; Tylki-Szymanska A
Curr Pharm Des; 2013; 19(33):6009-13. PubMed ID: 23448457
[TBL] [Abstract][Full Text] [Related]
17. Disease progress in patients with Morbus Fabry after switching from agalsidase beta to agalsidase alpha.
Reidt S; Namdar M; Serra A; Krayenbühl PA; Gruner C; Keller DI; Lüscher TF; Schmied C
Intern Med J; 2014 Feb; 44(2):205-7. PubMed ID: 24528819
[No Abstract] [Full Text] [Related]
18. Enzyme replacement therapy for Anderson-Fabry disease.
El Dib RP; Nascimento P; Pastores GM
Cochrane Database Syst Rev; 2013 Feb; (2):CD006663. PubMed ID: 23450571
[TBL] [Abstract][Full Text] [Related]
19. Fabry Disease and the Heart: A Comprehensive Review.
Azevedo O; Cordeiro F; Gago MF; Miltenberger-Miltenyi G; Ferreira C; Sousa N; Cunha D
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922740
[TBL] [Abstract][Full Text] [Related]
20. Lysosomal delivery of therapeutic enzymes in cell models of Fabry disease.
Marchesan D; Cox TM; Deegan PB
J Inherit Metab Dis; 2012 Nov; 35(6):1107-17. PubMed ID: 22450713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
